COVID-19 serology in nephrology healthcare workers.
Wien Klin Wochenschr
; 133(17-18): 923-930, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1173916
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
BACKGROUND:
Chronic kidney disease patients show a high mortality in cases of a severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) infection. Thus, information on the sero-status of nephrology personnel might be crucial for patient protection; however, limited information exists about the presence of SARS-CoV2 antibodies in asymptomatic individuals.METHODS:
We examined the seroprevalence of SARS-CoV2 IgG and IgM antibodies among healthcare workers of a tertiary care kidney center during the the first peak phase of the corona virus disease 2019 (COVID-19) crisis in Austria using an orthogonal test strategy and a total of 12 commercial nucleocapsid protein or spike glycoprotein-based assays as well as Western blotting and a neutralization assay.RESULTS:
At baseline 60 of 235 study participants (25.5%, 95% confidence interval, CI 20.4-31.5%) were judged to be borderline positive or positive for IgM or IgG using a high sensitivity/low specificity threshold in one test system. Follow-up analysis after about 2 weeks revealed IgG positivity in 12 (5.1%, 95% CI 2.9-8.8%) and IgM positivity in 6 (2.6%, 95% CI 1.1-5.6) in at least one assay. Of the healthcare workers 2.1% (95% CI 0.8-5.0%) showed IgG nucleocapsid antibodies in at least 2 assays. By contrast, positive controls with proven COVID-19 showed antibody positivity among almost all test systems. Moreover, serum samples obtained from healthcare workers did not show SARS-CoV2 neutralizing capacity, in contrast to positive controls.CONCLUSION:
Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV2 seroprevalence among asymptomatic individuals, while this was not the case among COVID-19 patients. TRIAL REGISTRATION NUMBER CONEC, ClinicalTrials.gov number NCT04347694.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Nephrology
Type of study:
Cohort study
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Wien Klin Wochenschr
Year:
2021
Document Type:
Article
Affiliation country:
S00508-021-01848-5
Similar
MEDLINE
...
LILACS
LIS